

**PCR-/NAT *Mycoplasma pneumoniae*
 (RV 541) Mai 2024**



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
541A 240521 01	∅	62	<i>Escherichia coli</i> K12
541A 240521 02	+++	61	<i>Mycoplasma pneumoniae</i> (~ 1x10 ⁶ genome copies/mL)
541A 240521 03	+	61	<i>Mycoplasma pneumoniae</i> (~ 5x10 ³ genome copies/mL)
541A 240521 04	∅	62	<i>Chlamydia pneumoniae</i> (~ 2x10 ⁴ IFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

n = 158	Proben Nr. (Sample no.)					Inhibition			
	01	02	03	04		01	02	03	04
Befund <i>Result</i>									
Positiv	0	158	112	0	n.d.	3	3	3	3
Negativ	158	0	42	158	nein <i>no</i>	155	155	155	155
Fraglich <i>Questionable</i>	0	0	4	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv <i>True positive results</i>				NAT richtig negativ <i>True negative results</i>			
	02		03		01		04	
	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%	Absolut <i>Absolute</i>	%
AID CAP bacteria (n = 6)	6	100	2	33	6	100	6	100
ARGENE C.pn / M.pn r-gene (n = 5)	5	100	3	60	5	100	5	100
Amplex eazyplex PneumoBug exp. (n = 5)	5	100	1	20	5	100	5	100
AmpliGnost M. pneumoniae (n = 4)	4	100	4	100	4	100	4	100
AmpliSens M.pn./C.pn. FRT Kit (n = 1)	1	100	1	100	1	100	1	100
AusDiagnostics Resp. Pathogens 24-well (n= 1)	1	100	1	100	1	100	1	100
BioGx auf BD Max (n = 6)	6	100	5	83	6	100	6	100
FILMARRAY Resp. Panel 2.1 plus (n = 3)	3	100	1	33	3	100	3	100

Biologio ReadyMax b-CAP Assay (n = 1)	1	100	1	100	1	100	1	100
FTD Atypical CAP (n = 1)	1	100	1	100	1	100	1	100
GeneProof M. pneumoniae (n = 12)	12	100	10[§]	100	12	100	12	100
Luminex MagPix Resp. Pathogen (n = 4)	4	100	0	0	4	100	4	100
Luminex NxTAG Resp. Pathogen + SARS-CoV-2 (n = 2)	2	100	0	0	2	100	2	100
Mikrogen Diagenode M.pn. /C.pn. (n = 1)	1	100	1	100	1	100	1	100
ampliCube Resp. panel 1 (n = 1)	1	100	1	100	1	100	1	100
ampliCube Resp. panel 1.1 /1.1LC (n = 12)	12	100	11	92	12	100	12	100
Alethia Mycoplasma direct (n = 3)	3	100	1	33	3	100	3	100
QIAstat-Dx Resp. Sars CoV-2 panel (n = 3)	3	100	2	67	3	100	3	100
Sacace M.pn./C.pn. Real-TM (n = 3)	3	100	3	100	3	100	3	100
Sartorius Microsart ATMP Myc. (n = 2)	2	100	0	0	2	100	2	100
Seegene Allplex Pneumobacter (n = 11)	11	100	8	73	11	100	11	100
Seegene Allplex Resp. Panel 4 (n = 17)	17	100	15	88	17	100	17	100
LightMix M. pneumoniae (n = 8)	8	100	7	88	8	100	8	100
RIDAGENE CAP Bac (n = 9)	9	100	4	44	9	100	9	100
In house PCR assay (n = 24)	24	100	18[§]	82	24	100	24	100
Other commercial tests (n = 13)	13	100	11	85	13	100	13	100

[§] Fraglich *Due to reporting questionable results, the number of true results has been reduced.*

Comments:

1. The following tests are listed under "Other commercial tests": CerTest VIASURE C. pneumonia, M. pneumonia and L. pneumophila Real Time PCR Detection Kit (CML172) (3x), QIAGEN QIAstat-Dx ME Panel (3x), ELITechGroup Respiratory Bacterial ELITe MGB Panel (2x), DNA-TECHNOLOGY C. pneumoniae, M. pneumoniae multiplex (1x) and PathoFinder RespiFinder 2Smart (1x).